Pulmovant Advances Mosliciguat Into Phase 3 After Positive PHocus Data
WALTHAM, Massachusetts — September 8, 2026 Pulmovant announced positive topline results from the Phase 2 PHocus study of mosliciguat...
Interstitial Lung Disease
Advertisement
Roivant and Pulmovant to Unveil Topline Mosliciguat Results in PH-ILD
Basel, Switzerland / London, UK / New York, NY — September 6, 2026 Roivant and Pulmovant announced that topline...
Evinova and Lothar Medical Partner to Modernize Respiratory Trials
Baar, Switzerland — September 5, 2026 Evinova announced a strategic partnership with Lothar Medical to modernize the execution of...
aTyr Pharma Awaits FDA Response on Efzofitimod Phase 3
SAN DIEGO, September 1, 2026 aTyr Pharma, Inc. expects to receive a response from the U.S. Food and Drug...
Evaxion Advances AI-Designed EVX-05 Brain Cancer Vaccine
Copenhagen, Denmark — August 17, 2026 Evaxion A/S has expanded and refocused its cancer vaccine pipeline with EVX-05, an...
Advertisements
United Therapeutics Completes TETON-PPF Phase 3 Enrollment
Silver Spring, Maryland & Research Triangle Park, North Carolina — August 17, 2026 United Therapeutics Corporation announced the full...
aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches
SAN DIEGO, August 7, 2026 aTyr Pharma reported its second quarter 2026 results and announced a corporate restructuring designed...
Parexel Showcases Oncology Research and Patient-Centered Innovation at ASCO 2026
RALEIGH, N.C. | May 28, 2026 Parexel announced that two oncology-focused research posters have been accepted for presentation at...
aTyr Pharma Advances Efzofitimod Phase 3 Sarcoidosis Program
SAN DIEGO, May 11, 2026 aTyr Pharma announced a major regulatory and clinical development update for its lead investigational...
FDA Fast Tracks ILD Imaging Radiotracer Innovation
LONDON, UK, Feb. 12, 2026 — Serac Healthcare announced that the U.S. Food and Drug Administration has granted Fast...
Advertisement
